C-Path in Europe: Moving Global Regulatory Science Forward

For more than a decade, the Critical Path Institute has worked with the European Medicines Agencies (EMA) to seek the endorsement of drug development tools and additional medical product solutions developed by its consortia. Additionally, it pursues a number of projects, initiatives and ventures each year in the EU as independent endeavours. C-Path’s strategic plan and priorities include expansion of its global strategy to best leverage its core competencies in regulatory and data science worldwide and facilitate global collaboration in areas of unmet need.

C-Path’s European nonprofit headquarters in the Netherlands officially launched in March 2022. Based in Amsterdam, the foundation pursues complementary opportunities to bolster existing and new partnerships with EU stakeholders. Like its U.S. counterpart, C-Path in EU also provides the legal and scientific infrastructure to create a uniquely neutral environment for industry, academia, patients, regulators and other government agencies.

Please join this webinar to learn more about how the nonprofit’s headquarters in Amsterdam will continue to improve public health, share expertise, data, risks, and costs to move global regulatory science forward by facilitating public-private partnerships with members from the biopharmaceutical industry, government regulatory agencies, academic institutions, and patient groups in Europe.

Speakers include C-Path scientific leadership who will present on-going activities on key topics such as Digital Technologies, Real-World Evidence, Model Informed Drug Development, and Complex Clinical Trials. Following presentations, audience questions will be answered by a panel of representatives from EFPIA, academia, EMA, and patient groups.

Find out more about C-Path Europe here. Register for the webinar here.